[Form 4] Twist Bioscience Corp Insider Trading Activity
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a non-discretionary sale on 09/22/2025 to satisfy tax withholding for vested restricted stock units. The filing shows 233 shares disposed at $27.56 per share and the reporting person held 102,710 shares following the transaction. The sale is described as a company-mandated "sell to cover" tied to equity plan withholding, not a voluntary trade by the insider.
The Form 4 was signed on 09/24/2025 by an attorney-in-fact. No other transactions or derivative positions are reported in this filing.
Dennis Cho, Senior Vice President, Chief Legal Officer e Corporate Secretary di Twist Bioscience Corp (TWST), ha riportato una vendita non discrezionale il 09/22/2025 per soddisfare la ritenuta fiscale delle vesting delle restricted stock units. La dichiarazione mostra la cessione di 233 azioni al prezzo di $27.56 per azione e la personache segnala deteneva 102,710 azioni dopo la transazione. La vendita è descritta come una vendita obbligata dall’azienda di tipo "sell to cover" legata alla trattenuta prevista dal piano azionario, non come un’operazione volontaria da parte dell’insider.
Il Form 4 è stato firmato il 09/24/2025 da un procuratore. Non sono riportate altre transazioni o posizioni derivate in questo fascicolo.
Dennis Cho, Vicepresidente Senior, Director Legal Principal y Secretario Corporativo de Twist Bioscience Corp (TWST), informó una venta no discrecional el 09/22/2025 para satisfacer la retención de impuestos de las unidades de acciones restringidas vestidas. La presentación muestra la disposición de 233 acciones a $27.56 por acción y la persona reportante poseía 102,710 acciones tras la operación.La venta se describe como una venta obligatoria de la empresa "sell to cover" ligada a la retención del plan de acciones, no como una operación voluntaria por parte del insider.
El Form 4 fue firmado el 09/24/2025 por un apoderado. No se reportan otras transacciones ni posiciones derivadas en este expediente.
Dennis Cho, Twist Bioscience Corp의 부사장 겸 최고법무책임자(CLO) 및 기업비서,는 09/22/2025에 vest 주식매수권(RSU) 보유로 인한 세금 원천징수를 충당하기 위한 비재량적 매도를 보고했습니다. 제출서는 233주를 $27.56에 처분했고, 보고자는 거래 후 102,710주를 보유하고 있음을 보여줍니다. 이 매도는 주식계획 원천징수와 관련된 회사가 지시한 "sell to cover" 방식으로 설명되며, 내부자의 자발적 거래가 아닙니다.
Form 4는 09/24/2025에 대리인에 의해 서명되었습니다. 이 공시에는 다른 거래나 파생 포지션이 보고되지 않았습니다.
Dennis Cho, Vice-président principal, Directeur juridique et Secrétaire général de Twist Bioscience Corp (TWST), a déclaré une vente non discrétionnaire le 22/09/2025 afin de satisfaire au prélèvement fiscal lié aux unités d’actions restreintes acquises. Le dossier indique la cession de 233 actions à $27,56 par action et la personne déclarant détenait 102 710 actions après la transaction. La vente est décrite comme une opération imposée par l’entreprise « sell to cover » liée au prélèvement du plan d’action, et non comme une transaction volontaire de l’insider.
Le Formulaire 4 a été signé le 24/09/2025 par un mandataire. Aucune autre transaction ou position dérivée n’est signalée dans ce dossier.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary der Twist Bioscience Corp (TWST), meldete am 22.09.2025 einen nicht-ermächtigenden Verkauf, um die Steuerabzug für vestete Restricted Stock Units zu erfüllen. Die Einreichung zeigt den Verkauf von 233 Aktien zu $27,56 pro Aktie, und die meldende Person hielt nach der Transaktion 102.710 Aktien. Der Verkauf wird als unternehmensseitig angeordneter „Sell to Cover“ im Zusammenhang mit der Aktienplanabzugsregelung beschrieben, nicht als freiwilliger Handel des Insiders.
Das Formular 4 wurde am 24.09.2025 von einem Bevollmächtigten unterschrieben. In diesem Filing sind keine weiteren Transaktionen oder Derivatepositionen gemeldet.
Dennis Cho، نائب رئيس أول، رئيس الشؤون القانونية وكاتب الشركة في Twist Bioscience Corp (TWST)، قد أبلغ عن بيع غير توتري في 09/22/2025 لتلبية اقتطاع الضريبة للوحدات المخزّنة المقيدة المكتسبة. يظهر الملف أن 233 سهماً تم التصرف فيها بسعر $27.56 للسهم، وأن الشخص المبلّغ ظل يملك 102,710 سهماً بعد المعاملة. يُوصف البيع بأنه "بيع لتغطية" من قبل الشركة مرتبط باقتطاع الخطة الأسهم، وليس صفقة طوعية من قبل المطلع. تم توقيع النموذج 4 في 09/24/2025 من قبل وكيل. لا توجد معاملات أخرى أو مراكز مشتقة مُبلَّغ عنها في هذا الملف.
Dennis Cho,Twist Bioscience Corp(TWST)的高级副总裁、首席法务官及公司秘书,已就为了满足已归属受限股票单位的税款扣缴而在2025-09-22进行了非自由裁量的出售并进行了报告。披露显示以每股$27.56的价格处置了233 股,报告人交易后持有102,710 股。此次出售被描述为公司强制的“sell to cover”,与股票计划扣缴相关,而不是内部人士的自愿交易。Form 4于2025-09-24由一名代理人签署。该披露中未报告其他交易或衍生头寸。
- Insider retained substantial ownership: Reporting person holds 102,710 shares after the transaction, indicating continued alignment with shareholders
- Transaction was non-discretionary: Sale described as a company-mandated "sell to cover" for RSU tax withholding, reducing signaling of negative insider sentiment
- None.
Insights
TL;DR: Routine sell-to-cover for RSU tax withholding; small single transaction relative to holdings, neutral for shareholders.
The disposition of 233 shares at $27.56 appears to be a standard administrative sale to satisfy tax obligations arising from RSU vesting. The insider still beneficially owns 102,710 shares, indicating continued substantial ownership and alignment with shareholders. Because the filing explicitly states the sale was mandated by the issuer's election under its equity plans and not discretionary, this transaction carries no new information about the insider's view on company prospects.
TL;DR: Administrative compliance action; reflects equity plan mechanics, not a change in governance or executive stance.
The Form 4 documents a compliance-driven sale to meet tax withholding from RSU vesting. The specificity that the sale was required under the issuer's election reduces concerns about opportunistic insider sales. The remaining beneficial ownership of 102,710 shares suggests ongoing executive stake. No governance issues, departures, or additional compensatory arrangements are disclosed in this filing.
Dennis Cho, Senior Vice President, Chief Legal Officer e Corporate Secretary di Twist Bioscience Corp (TWST), ha riportato una vendita non discrezionale il 09/22/2025 per soddisfare la ritenuta fiscale delle vesting delle restricted stock units. La dichiarazione mostra la cessione di 233 azioni al prezzo di $27.56 per azione e la personache segnala deteneva 102,710 azioni dopo la transazione. La vendita è descritta come una vendita obbligata dall’azienda di tipo "sell to cover" legata alla trattenuta prevista dal piano azionario, non come un’operazione volontaria da parte dell’insider.
Il Form 4 è stato firmato il 09/24/2025 da un procuratore. Non sono riportate altre transazioni o posizioni derivate in questo fascicolo.
Dennis Cho, Vicepresidente Senior, Director Legal Principal y Secretario Corporativo de Twist Bioscience Corp (TWST), informó una venta no discrecional el 09/22/2025 para satisfacer la retención de impuestos de las unidades de acciones restringidas vestidas. La presentación muestra la disposición de 233 acciones a $27.56 por acción y la persona reportante poseía 102,710 acciones tras la operación.La venta se describe como una venta obligatoria de la empresa "sell to cover" ligada a la retención del plan de acciones, no como una operación voluntaria por parte del insider.
El Form 4 fue firmado el 09/24/2025 por un apoderado. No se reportan otras transacciones ni posiciones derivadas en este expediente.
Dennis Cho, Twist Bioscience Corp의 부사장 겸 최고법무책임자(CLO) 및 기업비서,는 09/22/2025에 vest 주식매수권(RSU) 보유로 인한 세금 원천징수를 충당하기 위한 비재량적 매도를 보고했습니다. 제출서는 233주를 $27.56에 처분했고, 보고자는 거래 후 102,710주를 보유하고 있음을 보여줍니다. 이 매도는 주식계획 원천징수와 관련된 회사가 지시한 "sell to cover" 방식으로 설명되며, 내부자의 자발적 거래가 아닙니다.
Form 4는 09/24/2025에 대리인에 의해 서명되었습니다. 이 공시에는 다른 거래나 파생 포지션이 보고되지 않았습니다.
Dennis Cho, Vice-président principal, Directeur juridique et Secrétaire général de Twist Bioscience Corp (TWST), a déclaré une vente non discrétionnaire le 22/09/2025 afin de satisfaire au prélèvement fiscal lié aux unités d’actions restreintes acquises. Le dossier indique la cession de 233 actions à $27,56 par action et la personne déclarant détenait 102 710 actions après la transaction. La vente est décrite comme une opération imposée par l’entreprise « sell to cover » liée au prélèvement du plan d’action, et non comme une transaction volontaire de l’insider.
Le Formulaire 4 a été signé le 24/09/2025 par un mandataire. Aucune autre transaction ou position dérivée n’est signalée dans ce dossier.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary der Twist Bioscience Corp (TWST), meldete am 22.09.2025 einen nicht-ermächtigenden Verkauf, um die Steuerabzug für vestete Restricted Stock Units zu erfüllen. Die Einreichung zeigt den Verkauf von 233 Aktien zu $27,56 pro Aktie, und die meldende Person hielt nach der Transaktion 102.710 Aktien. Der Verkauf wird als unternehmensseitig angeordneter „Sell to Cover“ im Zusammenhang mit der Aktienplanabzugsregelung beschrieben, nicht als freiwilliger Handel des Insiders.
Das Formular 4 wurde am 24.09.2025 von einem Bevollmächtigten unterschrieben. In diesem Filing sind keine weiteren Transaktionen oder Derivatepositionen gemeldet.